|
Oral Presentation 10 COPD 2 |
12:50-13:30 |
||
|---|---|---|---|
| Chair | |||
| 10:30-10:40 | OP 10-1 |
Escalation Time to Open Triple Combination Therapy from the Initiation of LAMA Versus ICS/LABA in COPD Management: Findings from the Comparing the Incidence of Tiotropium and ICS/LABA in Real-World Use in South Korea (CITRUS) Study
|
|
| 10:40-10:50 | OP 10-2 |
Assessment of Satisfaction with the Inhaler and Determinants of High Satisfaction in COPD Patients
|
|
| 10:50-11:00 | OP 10-3 |
Comparison of Pneumonia Incidence between LAMA and ICS/LABA in Patients with COPD : A Retrospective Cohort Study in a Real-world Setting
|
|
| 11:00-11:10 | OP 10-4 |
Comparison of Risk of Pneumonia Caused by Fluticasone Versus Budesonide in Chronic Obstructive Pulmonary Disease: A Nationwide Retrospective Cohort Study
|
|
| 11:10-11:20 | OP 10-5 |
Association between Inhaled Corticosteroids Use and the Risk of Future Exacerbation in Patients with GOLD Group A Chronic Obstructive Pulmonary Disease
|
|
| 11:20-11:30 | OP 10-6 |
Seasonal Variations in PM2.5 Concentrations and Clinical Impact on Chronic Obstructive Lung Disease Patients
|
|
| 11:30-11:40 | OP 10-7 |
Clinical Implication in COPD Assessment Test Score Changes among Newly Diagnosed COPD Patients Treated with Bronchodilators
|
|
| 11:40-11:50 | OP 10-8 |
Diaphragm Ultrasound is an Image Biomarker of AECOPD
|
|
| 11:50-12:00 | OP 10-9 |
Systemic Antibiotics Can Deteriorate Emphysema Associated with Exaggerated Inflammation and Autophagy
|
|